Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Despite the absence of operational and strategic updates, the financial performance shows a positive trend with revenue, net income, EBITDA, and operating margin all improving year-over-year. The company's ability to increase cash flow from operations further supports a positive outlook. The lack of concerning responses in the Q&A suggests no immediate risks were highlighted, which maintains the positive sentiment.
Revenue Revenue for Q1 2026 was $30.5 million, representing a 12% increase year-over-year. This growth was driven by an increase in membership sales and higher patient visits.
Net Income Net income for Q1 2026 was $2.1 million, up from $1.8 million in Q1 2025, reflecting a 16.7% increase. The improvement was attributed to operational efficiencies and cost management.
EBITDA EBITDA for Q1 2026 was $5.3 million, a 10% increase compared to $4.8 million in Q1 2025. This was due to higher revenue and improved cost controls.
Operating Margin Operating margin improved to 17.4% in Q1 2026 from 16.2% in Q1 2025, driven by better cost management and increased revenue.
Cash Flow Cash flow from operations was $4.7 million in Q1 2026, up 14% from $4.1 million in Q1 2025, primarily due to higher net income and efficient working capital management.
The selected topic was not discussed during the call.
Forward-looking statements: The company's forward-looking statements involve risks and uncertainties that could cause actual future results, performance, and business prospects to differ materially from expectations. These risks are outlined in the Risk Factors section of the company's SEC filings.
The selected topic was not discussed during the call.
The selected topic was not discussed during the call.
Despite the absence of operational and strategic updates, the financial performance shows a positive trend with revenue, net income, EBITDA, and operating margin all improving year-over-year. The company's ability to increase cash flow from operations further supports a positive outlook. The lack of concerning responses in the Q&A suggests no immediate risks were highlighted, which maintains the positive sentiment.
Despite positive full-year financial performance and optimistic marketing initiatives, the decline in comp sales and lack of specific metrics on attrition and new patient adds raise concerns. The cautious approach to pricing increases and the shift from local to national marketing may not yield immediate results. The Q&A revealed some positive signs, but uncertainties remain. Overall, the market may react neutrally over the next two weeks.
The earnings call presents strong financial performance with improved net income, EBITDA, and revenue growth. The strategic shift towards refranchising and pricing adjustments, alongside a new marketing focus, is promising. Despite some uncertainties in refranchising timelines, management's confidence and strategic initiatives, such as the app launch and marketing strategy, suggest a positive outlook. Analysts seem cautiously optimistic, with concerns mainly around refranchising timing and pricing strategies, but these are being actively addressed. Overall, the company's strategic direction and operational improvements indicate a likely positive stock reaction.
The earnings call shows improvement in financial health, with a shift from net loss to net income and increased cash reserves. Though guidance was lowered due to macroeconomic headwinds, management is proactively addressing these issues. The refranchising strategy and cost reduction efforts are positively impacting profitability. While some concerns remain about new patient acquisition and unclear guidance on EBITDA, the overall sentiment is positive due to strategic initiatives and improved financial performance.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.